AKT1 and plasma cell myeloma: Perifosine, an alkylphospholipid PI3K-AKT inhibitor, is an anti-tumor compound that alters the composition of lipid rafts of the plasma membrane, and has been subjected to phase III trials for colorectal cancer and multiple myeloma.